The burden of cancer in Spain

X. Badía ^[2] ; M. Tort ^[2] ; A.-G. Manganelli ^[2] ; C. Camps ^[1] ; E. Díaz-Rubio ^[3]
1. [1] Hospital General Universitario de Valencia
  
  Hospital General Universitario de Valencia
  
  Valencia, España
2. [2] Omakase Consulting S.L., Barcelona
3. [3] Real Academia Española de Medicina, Madrid
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 6, 2019, págs. 729-734
Idioma: inglés
Texto completo no disponible (Saber más ...)

Resumen
- Introduction Cancer imposes a huge financial burden in all developed countries. This study estimates the burden of cancer in Spain in 2015.
  
  Methods The most recent available epidemiological data on prevalence, incidence and mortality, and the economic data on direct (hospital, drugs, and primary care) and indirect (productivity) costs was used from the social perspective.
  
  Results Prevalence, incidence, and mortality were, respectively, 1240, 478, and 218 per 100,000 inhabitants. Mortality was higher for men, while disability rates were higher for women. Direct costs accounted for 4818 million euros and indirect costs were 640 million euros in 2015. Direct costs were almost completely borne by the hospital (94%). Total burden of cancer in Spain was 5458 million euros in 2015.
  
  Conclusions In Spain, the costs of cancer were mainly borne by the hospital and these costs might increase in the future due to the expected increase in longevity. Further research would be needed to investigate whether it is possible to redistribute the economic burden of cancer.